Dr. Scott Rocklage is one of the managing partners at 5 AM ventures. He is a renowned figure in the fields of health care and entrepreneurship. Dr. Rocklage has been in the healthcare business for the past three decades. Therefore, he has a rich medical knowledge as well as astounding strategic leadership and management skills.
Scott has conducted a lot of research that has led to the evolution of new drugs and pharmaceuticals. Some of the products he has developed include Omniscan, Teslacan, and Cubicin, which are all FDA approved. He also has six new drugs undergoing clinical trials.
Scott Rocklage joined 5 AM venture in 2001 as a venture partner. A year later, his expertise was noted, and that helped him become a managing partner.
He has also served at the Cubist Pharmaceuticals as the chairman and CEO of the company. Besides his current role as managing partner at 5 AM, he is the chairman of the Boards of Semprus, Relypsa, and Achaogen.
The health care expert is affiliated with several health organizations. This is attributed to his elaborate expertise in medicine-related issues. Scott is a board member of the Institute Board of Associates. He is also the chairman of the Boards of Kinestral, Rennovia, and Ciadara Therapeutics.
Scott Rocklage also has a broad educational background. He attained a bachelor’s degree in Chemistry at the University of California. After that, he undertook a Ph.D. in chemistry at Massachusetts Institute of Technology.
While pursuing his Ph.D., Dr.Rocklage worked closely with Richard R. Schrock – the 2005’s Nobel Prize winner. Scott carried out all his research in Richard Shrock’s lab. He later innovated and co-invented more than 30 drug patents in the US. He has published over 100 texts which most medical experts have found extremely useful. Read more: Scott Racklage | Crunchbase and Scott Racklage | Bloomberg
Dr. Scott Rocklage’s Company, 5 AM ventures, is venture capital firm based in California. The company avails capital to life sciences start-ups in their early stages, hence its name 5 AM. Scott works with scientists, physicians, and business executives who have shown interest in the pharmaceutical industry.
He provides such clients with the infrastructure that help can them develop potential drugs to address the rising health problems.
Currently, Dr. Rocklage seeks to exploit evolving healthcare technology to cure stubborn diseases such as cancer.
For instance, he is particularly excited about the innovation that targets specific mutations or genomes in cancer patients for an effective treatment.